GERON CORP (GERN): Results of Operations and Financial Condition
GERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product rev
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations for RYTELO revenue trajectory using Q2 net product revenue, demand growth, ordering accounts, and the reiterated 2026 revenue and operating expense ranges. The filing also provides context for ongoing clinical/scientific activity via EHA and ASCO presentations, but the immediate tradable catalyst is the guidance and quarterly financials.
Market read
Fresh quarterly revenue, demand, and explicit 2026 guidance ranges make this a direct expectation-setting update for GERN’s commercial-stage hematology story.
What to watch
Cash balance declined from $341.0M (Mar 31) to about $326.9M (Jun 30), and operating expense guidance includes non-cash items, which can mask underlying cash burn dynamics.
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
RYTELO net product revenue reached $57.5 million and increased 11% compared to Q1 2026, but total costs and operating expenses rose to $70.0 million and the Company reported a net loss of $16.7 million. The Company reiterated its 2026 revenue and operating-expense ranges.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RYTELO net product revenueother | $57.5 million | 11% | – |
| Total product revenue, netother | $57.5 million | – | – |
| Net lossother | $16.7 million | – | – |
| Net loss per shareother | $0.02 per share | – | – |
| Total costs and operating expensesother | $70.0 million | – | – |
| Cost of goods soldother | approximately $9.2 million | – | – |
| Research and development expensesother | $22.0 million | – | – |
| Selling, general and administrative expensesother | $38.9 million | – | – |
| RYTELO demand growthother | 5% | 5% | – |
| Ordering accountsother | approximately 1,575 | roughly 8% | – |
| Cash, cash equivalents, restricted cash and marketable securitiesother | approximately $326.9 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| RYTELORYTELO demand grew by 5% in the second quarter 2026 compared to the first quarter 2026, and ordering accounts increased by roughly 8% to approximately 1,575. | $57.5 million | 11% | – |
fiscal year 2026 outlook
- Revenue$220 million to $240 million
- Operating expenses$230 million to $240 million
- NoteTotal operating expenses include non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, inventory write-offs, depreciation and amortization.
What drove it
- RYTELO net product revenue was $57.5 million in the second quarter of 2026 and increased 11% compared to Q1 2026.
- RYTELO demand grew by 5% in the second quarter 2026 compared to the first quarter 2026.
- Ordering accounts increased by roughly 8% to approximately 1,575.
- The increase in net loss was directly attributable to non-cash inventory-related expenses, partially offset by increased RYTELO net product revenue.
- Cost of goods sold increased primarily due to non-cash inventory-related expenses.
- Research and development expense increased as a result of investments in manufacturing and was partially offset by lower headcount costs from the workforce reduction in December 2025.
- Selling, general and administrative expense reflected continued investment in RYTELO commercialization and lower general and administrative expenses primarily due to decreased personnel expense from the workforce reduction in December 2025.
Concerns
- Total costs and operating expenses were $70.0 million, compared to $61.5 million for the three months ended June 30, 2025.
- Cost of goods sold was approximately $9.2 million, compared to $1.2 million for the three months ended June 30, 2025, primarily due to non-cash inventory-related expenses.
- The Company reported a net loss of $16.7 million.
- Cash, cash equivalents, restricted cash and marketable securities were approximately $326.9 million as of June 30, 2026, compared to $341.0 million as of March 31, 2026.
What to watch
- RYTELO net product revenue progress against the fiscal-year 2026 range of $220 million to $240 million.
- Total operating expenses against the fiscal-year 2026 range of $230 million to $240 million.
- Continued RYTELO demand growth and ordering-account expansion.
- Progress in the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis.
- Potential pathways to bring RYTELO to patients outside of the U.S.
Balance sheet and cash flow
- As of June 30, 2026, Geron had approximately $326.9 million in cash, cash equivalents, restricted cash and marketable securities, compared to $341.0 million as of March 31, 2026.
- The Company believes that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future.
Analysis
Geron reported $57.5 million in RYTELO net product revenue for the second quarter of 2026, which was also reported as total product revenue, net. Revenue was $49.0 million in the comparable 2025 period, while the release separately stated that RYTELO net product revenue increased 11% compared to Q1 2026. Commercial activity continued to build, with RYTELO demand up 5% sequentially and ordering accounts increasing by roughly 8% to approximately 1,575.
The revenue gain did not translate to lower reported losses in the quarter. Geron posted a net loss of $16.7 million, or $0.02 per share, versus a net loss of $16.4 million, or $0.02 per share, in the prior-year period. Management attributed the increase in net loss directly to non-cash inventory-related expenses, partly offset by higher RYTELO net product revenue.
Total costs and operating expenses rose to $70.0 million from $61.5 million. Cost of goods sold increased to approximately $9.2 million from $1.2 million, with the increase primarily attributed to non-cash inventory-related expenses. Research and development expenses were $22.0 million versus $21.7 million, reflecting manufacturing investments that were partly offset by lower headcount costs following the December 2025 workforce reduction. Selling, general and administrative expenses were $38.9 million versus $38.6 million as commercialization investment continued while personnel-related general and administrative costs declined.
Liquidity was approximately $326.9 million in cash, cash equivalents, restricted cash and marketable securities at June 30, 2026, compared with $341.0 million at March 31, 2026. The Company stated that existing liquidity together with anticipated U.S. RYTELO net revenues will be sufficient to fund projected operating requirements for the foreseeable future. No debt balance, operating cash flow, free cash flow, share repurchases, or dividends were reported in the provided filing text.
Geron reiterated fiscal-year 2026 guidance for RYTELO net product revenue of $220 million to $240 million and total operating expenses of $230 million to $240 million. The outlook preserves the commercial-growth and expense-discipline targets while explicitly noting that operating expenses include stock-based compensation, debt-discount and issuance-cost amortization, inventory write-offs, depreciation and amortization. Business execution beyond current U.S. commercialization includes potential expansion into other geographies and advancement of the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis.
Management, verbatim
We are executing a focused strategy to build a leading hematology company, which starts with bringing RYTELO to more eligible patients impacted by LR-MDS in the U.S. Our team delivered a third consecutive quarter of RYTELO demand growth, and in the first half of 2026, grew net revenue by 24% while decreasing total operating expenses by 4% compared to the same period last year.
Harout Semerjian, President and Chief Executive Officer of Geron
Not in the filing
stated, not guessed- GAAP designation for reported financial metrics was not stated in the provided filing text.
- Non-GAAP revenue, gross margin, operating income or loss, net income or loss, and EPS were not reported.
- Gross profit and gross margin were not reported.
- Operating income or loss and operating margin were not reported.
- Prior-quarter RYTELO net product revenue was not reported.
- Percentage year-over-year changes for total product revenue, net loss, total costs and operating expenses, cost of goods sold, research and development expenses, and selling, general and administrative expenses were not reported.
- Operating cash flow and free cash flow were not reported.
- Debt balance was not reported.
- Capital returns, including share repurchases and dividends, were not reported.
- Guidance for gross margin and tax rate was not reported.
- Previous outlook was not provided, so no comparison of reported results with prior guidance is available.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC 8-K (Item 2.02) reports Geron’s Q2 2026 financial results and business highlights for RYTELO (imetelstat), including updated cash position and 2026 guidance ranges.
Ticker impact
Geron reported Q2 2026 RYTELO net product revenue of $57.5M and reiterated 2026 revenue guidance of $220M to $240M.
Moderate upside bias if investors view the 11% Q/Q revenue growth and reiterated 2026 ranges as credible; downside risk if margins or cash burn concerns dominate.
The filing includes fresh, decision-relevant datapoints: Q2 revenue, demand growth, cash balance, and explicit 2026 revenue and operating expense ranges. However, it does not provide new trial readouts that would re-rate the long-term probability distribution beyond conference presentations.
Market effects
Adds incremental datapoints on commercial-stage telomerase inhibitor demand in LR-MDS, relevant for sentiment toward hematology biopharma commercialization.
Primarily US-focused read-through via Nasdaq-listed issuer and US patient opportunity framing.
EHA and ASCO real-world evidence and abstracts support international scientific validation, but the financial guidance is US-centric.
Counterpoint
Non-cash inventory-related expenses drove the higher net loss, so headline revenue growth may not translate into cleaner operating leverage.
Key entities
- companyGeron Corporation
Commercial-stage biopharmaceutical company reporting Q2 2026 results and reiterating 2026 RYTELO revenue and operating expense guidance.
- productRYTELO (imetelstat)
Approved telomerase inhibitor for LR-MDS with transfusion-dependent anemia; the filing reports Q2 net product revenue and demand metrics.
- executiveChinmaya Rath
Appointed Chief Business Officer, expanding the leadership team per the business highlights section.
